Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Pharmaceuticals' Q4 Profit Surges 51% on Strong Eylea Sales

By Sean Williams – Feb 11, 2014 at 1:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Impressive Eylea sales growth within and outside the U.S., as well as increased collaborative revenue, pushes Regeneron's profit up 51%.

Shareholders in the rapidly growing Regeneron Pharmaceuticals (REGN -1.43%) can certainly see a little clearer now after the company reported robust top- and bottom-line growth in the fourth quarter before the opening bell today.

For the quarter, Regeneron reported a 47% increase in total revenue to $610 million as adjusted net income jumped 51% to $259 million from $171 million in the year-ago period. On an adjusted basis, that works out to $2.24 per diluted share in EPS.

The big story, of course, is the company's wet age-related macular degeneration drug Eylea, which earned blockbuster status this year, hitting $1.41 billion in U.S. sales and $402 million in net product sales this quarter within the U.S. Sales of Eylea outside the U.S., where partner Bayer (BAYR.Y -3.65%) holds licensing rights, hit $184 million. Comparatively speaking, Eylea sales within the U.S. were just $276 million during the fourth quarter last year and a mere $19 million outside the U.S. This rest-of-the-world figure is important for Regeneron as it helped the company earn an additional net profit of $44 million during the quarter.

Collaborative revenue and milestone payments were another key source of growth for Regeneron. During the quarter, collaborative revenue increased 55% to $197 million primarily due to the commercialization of Eylea outside the U.S., and because of a $25 million milestone payment received from Bayer.

Regeneron isn't content sitting on its hands, either. Because of Eylea's commercial rollout and its churning pipeline of products Regeneron's research and development expenses rose to $268 million in the fourth quarter from just $181 million last year at this time. Similarly, selling, general, and administrative expenses also rose substantially to $82 million from $58 million year over year.

Looking ahead, Regeneron anticipates net Eylea product sales of $1.7 billion-$1.8 billion in 2014, representing 24% growth at the midpoint, with $350 million-$425 million projected in capital expenditures and $425 million-$475 million in adjusted, unreimbursed R&D expenses.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
REGN
$755.45 (-1.43%) $-10.94
Bayer Aktiengesellschaft Stock Quote
Bayer Aktiengesellschaft
BAYR.Y
$13.98 (-3.65%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.